Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
amphotericin B liposomal (CSPC Zhongnuo Pharmaceutical)
- Development stage
- Unknown
- Lead developer
- CSPC Zhongnuo Pharmaceutical
- Modality
- Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Small Molecules
- Administration
- Intravenous
01
Overview
Amphotericin B liposomal (CSPC Zhongnuo Pharmaceutical) is a generic, bioequivalent formulation of the reference antifungal drug AmBisome, developed by CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. The drug consists of the polyene antifungal agent amphotericin B encapsulated within a liposomal delivery system. Its mechanism of action involves binding to ergosterol, a key component of fungal cell membranes, which results in the formation of transmembrane pores, leakage of essential intracellular ions (such as potassium), and fungal cell death. The liposomal formulation is specifically designed to reduce the significant nephrotoxicity associated with conventional amphotericin B deoxycholate while maintaining broad-spectrum efficacy. It is primarily being developed for the treatment of invasive fungal infections and persistent febrile neutropenia, with clinical development reaching Phase III trials.
- Other names
- Amphotericin B liposome for injectionLiposomal amphotericin B
02
Targets
Ergosterol
Beyond the preview
Go deeper on amphotericin B liposomal (CSPC Zhongnuo Pharmaceutical).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on amphotericin B liposomal (CSPC Zhongnuo Pharmaceutical).